Business, energy, technology, markets and global industry news from Business News Today

non-Hodgkin lymphoma

PharmaDeviceNews non-Hodgkin lymphoma
Representative image of a clinical oncology research setting as PeproMene Bio’s PMB-CT01 BAFF-R CAR T data highlight a potential new treatment path for relapsed B-cell lymphoma after CD19 CAR T failure.
Pharma & Biotech

PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma

PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.

Read More
Representative image illustrating antibody-targeted therapy in lymphoma treatment, relevant to Japan’s approval of tafasitamab for relapsed follicular lymphoma.
Pharma & Biotech

Incyte’s Minjuvi combo gets Japan approval for relapsed follicular lymphoma

Incyte Biosciences Japan has secured approval from the Ministry of Health, Labour and Welfare for the use of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. This marks the first regulatory authorization in Japan for a CD19-directed therapy in this indication and introduces a novel CD19–CD20

Read More